HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mário Mourão Netto Selected Research

Ductal Carcinoma

7/2007C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mário Mourão Netto Research Topics

Disease

6Neoplasms (Cancer)
02/2011 - 10/2005
5Breast Neoplasms (Breast Cancer)
02/2011 - 10/2005
1Lymphatic Metastasis
05/2010
1Ductal Carcinoma
07/2007
1Carcinoma in Situ
09/2006
1Carcinoma (Carcinomatosis)
09/2006
1Necrosis
09/2006
1Lobular Carcinoma
09/2006

Drug/Important Bio-Agent (IBA)

3Proteins (Proteins, Gene)FDA Link
02/2011 - 11/2007
2Phenobarbital (Luminal)FDA Link
02/2011 - 07/2010
1Cysteine (L-Cysteine)FDA Link
02/2011
1Biomarkers (Surrogate Marker)IBA
02/2011
1Progesterone Receptors (Progesterone Receptor)IBA
05/2010
1Hormones (Hormone)IBA
05/2010
1Estrogen ReceptorsIBA
05/2010
1platelet protein P47 (pleckstrin)IBA
11/2007
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
11/2007
1Messenger RNA (mRNA)IBA
11/2007
1Galectin 3 (LGALS3)IBA
07/2007
1Colloids (Colloid)IBA
09/2006
1Doxorubicin (Adriamycin)FDA LinkGeneric
10/2005

Therapy/Procedure

3Therapeutics
07/2010 - 10/2005
1Neoadjuvant Therapy
05/2010
1Adjuvant Chemotherapy
05/2010
1Drug Therapy (Chemotherapy)
10/2005